{"commentary":{"count":102,"free_build_floor":8,"listing_floor":3,"by_channel":{"x_thread":64,"youtube":20,"podcast":18},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05089734\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"EVOKE-01","nct_id":"NCT05089734","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=evoke-01-nct05089734. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 41+ commentary sources"},"registry":{"acronym":"EVOKE-01","arms":[{"description":"Participants will receive SG 10 mg/kg on Days 1 and 8 of a 21-day cycle (ie, 2 weekly doses plus 1 week without treatment) until progressive disease (PD), death, unacceptable toxicity, or another treatment discontinuation criterion is met.","label":"Sacituzumab Govitecan-hziy (SG)","type":"EXPERIMENTAL"},{"description":"Participants will receive docetaxel 75 mg/m\\^2 on Day 1 of a 21-day cycle (ie, once every 3 weeks) until PD, death, unacceptable toxicity, or another treatment discontinuation criterion is met.","label":"Docetaxel","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2027-01","type":"ESTIMATED"},"conditions":["Non-Small Cell Lung Cancer"],"enrollment":{"count":603,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Sacituzumab Govitecan-hziy (SG)","type":"BIOLOGICAL"},{"name":"Docetaxel","type":"DRUG"}],"last_update":"2026-05-07","lead_sponsor":"Gilead Sciences","official_title":"Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2023-11-29","type":"ACTUAL"},"primary_outcomes":[{"measure":"Overall Survival (OS)","timeFrame":"Up to 24.4 months"}],"references":[{"citation":"Paz-Ares LG, Juan-Vidal O, Mountzios GS, Felip E, Reinmuth N, de Marinis F, Girard N, Patel VM, Takahama T, Owen SP, Reznick DM, Badin FB, Cicin I, Mekan S, Patel R, Zhang E, Karumanchi D, Garassino MC. Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study. J Clin Oncol. 2024 Aug 20;42(24):2860-2872. doi: 10.1200/JCO.24.00733. Epub 2024 May 31.","pmid":"38843511","type":"DERIVED"}],"start_date":{"date":"2021-11-17","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Sacituzumab Govitecan (SG) Versus Docetaxel in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)","url":"https://clinicaltrials.gov/study/NCT05089734"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/evoke-01-nct05089734"}